Can severe asthma lead to COPD?
Overview
Severe and poorly controlled asthma can lead to damaged lungs which may increase the risk of developing chronic obstructive pulmonary disease (COPD). Symptoms of asthma and COPD may frequently co-exist in smokers and the elderly.
Features of both asthma and COPD can overlap in some patients initially diagnosed with either COPD or asthma alone. In the medical community, this may be called the “asthma-COPD overlap” (ACO). ACO is a description of clinical features, not a single disease.
Identifying patients with ACO is important to help guide treatment, but clinical features may differ from patient to patient. ACO is estimated to occur in roughly 2% to 3% of the general population, but is much higher in those first diagnosed with asthma (13% to 61%) or COPD (12% to 55%).
How do you diagnose ACO?
Asthma-COPD overlap (ACO) is not one defined disease but is most likely a combination of symptoms and mechanisms of airways disease. Outcomes can be worse for ACO compared to either asthma COPD alone. Specialized doctors such as a pulmonologist may be needed for diagnosis and treatment of patients.
Proposed diagnostic features of the “asthma-COPD overlap” (ACO) according to the Global Initiative for Asthma (GINA) include:
- Age 40 years or older
- Breathing symptoms such as shortness of breath upon exertion
- Spirometry (lung function tests): FEV1/FVC <0.7 or the lower limit of normal, with a bronchodilator increase in FEV1 >12% and 400 mL
- A history of asthma diagnosed medically
- A history of allergies or a genetic tendency to develop allergies (such as allergic rhinitis, asthma and eczema)
- Having a risk factor (≥10 pack years tobacco smoking, airborne pollutants)
In some cases, blood tests or a chest x-ray may be needed
How do you treat ACO?
There is limited randomized clinical trial data on how to treat patients with ACO, because their mixed symptoms often exclude them from clinical studies. More studies are needed in this patient group.
Pharmacologic (drug) therapies
General proposed drug therapies for ACO focus on treatments used in both asthma and COPD and are based on expert opinion from GINA and GOLD guidelines. Drug therapies are often used in stepwise fashion based on response, and include:
- Short-acting bronchodilators for as-needed relief (short-acting beta agonist, short-acting muscarinic antagonist, or a combination)
- Inhaled corticosteroids (ICS) in a low-to-moderate dose
- If symptoms warrant: a long-acting beta-agonist (LABA) / long-acting muscarinic antagonist (LAMA) to control additional symptoms.
- Combination ICS-LABA therapies can be used, but avoid use of long-acting beta-agonist (LABA) therapy alone (as in asthma).
- For persistent symptoms after a stepwise approach, other options may include triple therapy with LAMA-LABA-ICS or biologic agents developed for severe allergic asthma.
Non-drug therapies
Lifestyle and nondrug therapies are also a cornerstone of treatment in ACO, and include:
- Smoking cessation and avoidance of airborne pollutants
- Keeping vaccinations up to date (influenza, pneumococcal, COVID)
- Allergen avoidance, when possible
- Physical exercise, when appropriate
- Pulmonary rehabilitation
- Educational programs (inhaler technique, keeping active)
Learn more:
Related questions
Bottom Line
- Severe and poorly controlled asthma can lead to damaged lungs which may increase the risk of developing chronic obstructive pulmonary disease (COPD).
- Features of both asthma and chronic obstructive pulmonary disease (COPD) can overlap in some patients initially diagnosed with COPD or asthma, and may be called the “asthma-COPD overlap” (ACO).
- Identifying patients with ACO is important to help guide treatment, but clinical features and appropriate treatments may differ from patient to patient. Drug treatments include agents used commonly in both asthma and COPD.
References
- Pocket Guide for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Updated 2021. Accessed Dec. 9, 2021 at https://ginasthma.org/wp-content/uploads/2021/05/GINA-Pocket-Guide-2021-V2-WMS.pdf
- Wurst KE, Kelly-Reif K, Bushnell GA, et al. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med. 2016 Jan;110:1-11. doi: 10.1016/j.rmed.2015.10.004. Epub 2015 Oct 9. Accessed Dec. 9, 2021.
- King Han M. Asthma and COPD overlap. Up to Date. Accessed Dec. 9, 2021 at https://www.uptodate.com/contents/asthma-and-copd-overlap-aco/
- Ask the Allergist: Does Chronic Asthma Lead to COPD. Accessed Dec. 9, 2021 at https://allergyasthmanetwork.org/news/does-chronic-asthma-lead-copd/
- Asthma, COPD, and Asthma-COPD overlap syndrome (ACOS). Global Initiative for Asthma (GINA) / Global Initiative for Chronic Obstructive Lung Disease. Accessed Dec. 9, 2021 at https://goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf
Read next
What is considered severe asthma?
Severe asthma is when you require medium to high-dose inhaled corticosteroids combined with other longer-acting medications. Severe asthma can also be defined as having a peak expiratory flow rate (PEF or PEFR) less than 50% of your personal best. This shows severe narrowing of your large airways and is considered a medical emergency and you should get help right away. Your symptoms may include coughing, being very short of breath, wheezing while breathing in and out, or retractions (this is when you can see the muscles between the ribs working hard to keep you breathing). Walking and talking may also be difficult. Continue reading
Which measure is the single best determinant of asthma severity?
A peak expiratory flow rate (PEF or PEFR) is the single best determinant of asthma severity. A PEF measurement is a quick test to measure air flowing out of the lungs. During the test, you blow forcefully into the mouthpiece of a device, usually a peak flow meter (PFM), which is a portable, light, handheld device made of plastic. If the test is done in a healthcare provider's office or a hospital a much larger device, called a spirometer, is usually used. This device has a handheld mouthpiece that’s attached by a cord to a larger electronic machine. Continue reading
Does Cinqair treat all types of asthma?
Cinqair (reslizumab) does not treat all types of asthma. It has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance therapy to treat patients with severe asthma, aged 18 years and older, who have an eosinophilic phenotype.
Cinqair is not used to treat other types of asthma, other eosinophilic conditions, or used as a rescue medication for asthma attacks. Continue reading
See also:
Related medical questions
- What's a good prednisone taper schedule?
- Prednisone: What are 12 Things You Should Know?
- Prednisone vs Prednisolone - What's the difference?
- What are the side effects of steroids?
- Can vitamin C prevent or treat COVID-19 (coronavirus)?
- What is Diprospan used for?
- Can asthma inhalers cause a sore throat?
- What is the difference between Breztri vs Trelegy?
- Trelegy vs. Breo: How does their use and cost compare?
- What is Quercetin and what are its health benefits?
- Is Dupixent an immunosuppressant?
- Why do insurance companies deny Dupixent?
- How does the Dupixent Myway copay card work?
- How does Dupixent work and what is its mechanism of action?
- Does coffee help with asthma?
- Can you drink alcohol on Dupixent?
- Can you take Symbicort and prednisone together?
- Why is Breztri not for asthma?
- Is Wixela Inhub the same as Advair Diskus?
- How do Rinvoq and Dupixent compare?
- Does Feverfew interact with any drugs?
- Can you take Trelegy and Symbicort together?
- Does Fasenra weaken your immune system?
- What are 5 key Tezspire side effects to watch out for?
Related support groups
- Asthma (129 questions, 474 members)
- Chronic Obstructive Pulmonary Disease (137 questions, 492 members)